What is SomaLogic?
SomaLogic operates at the critical intersection of biotechnology and big data, specializing in proteomics—the large-scale study of proteins. The company's core platform is engineered to deliver high-throughput analysis, enabling researchers and clinicians to gain deeper insights into biological systems at a reduced cost. By maintaining low limits of detection and high reproducibility, SomaLogic has positioned itself as an essential partner for organizations focused on molecular diagnostics, drug discovery, and precision medicine. Its market position is reinforced by a history of strategic partnerships with global pharmaceutical entities and specialized life science investment firms.
How much funding has SomaLogic raised?
SomaLogic has raised a total of $1.3B across 11 funding rounds:
Private Equity
$10M
Unspecified
$1M
Private Equity
$16.5M
Private Equity
$60.5M
Private Equity
$163M
Private Equity
$44.9M
Private Equity
$200M
Debt
$2M
Series A
$214M
Stock Offering
$630M
Private Equity (2013): $10M, investors not publicly disclosed
Unspecified (2014): $1M supported by Bill & Melinda Gates Foundation
Private Equity (2014): $16.5M, investors not publicly disclosed
Private Equity (2016): $60.5M backed by Visium Healthcare Partners
Private Equity (2016): $163M, investors not publicly disclosed
Private Equity (2017): $44.9M, investors not publicly disclosed
Private Equity (2018): $200M supported by Visium Healthcare Partners, Quest Diagnostics, Nan Fung Life Sciences, iCarbonX, ProQuest Investments, Madryn Asset Management, and Otsuka Pharmaceutical
Debt (2020): $2M featuring PPP
Series A (2020): $214M backed by Logos Capital, Janus Henderson Investors, T. Rowe Price Associates, Mossrock Capital, Boston Millennia Partners, Redmile Group, Soleus Capital, Remagine Ventures, Blue Water Life Science Advisors, Madryn Asset Management, Monashee Investment Management, Millennium Management, Fiscus Ventures, Casdin Capital, Ziff Capital Healthcare Ventures, Revelation Partners, Foresite Capital, and Farallon Capital Management
Stock Issuance/Offering (2021): $630M with participation from T. Rowe Price, Corvex Management, Janus Henderson Investors, Casdin Capital, and SB Management
Key Investors in SomaLogic
T. Rowe Price
A global investment management firm providing equity and fixed income solutions to institutional and individual clients, known for its disciplined, research-driven approach to long-term capital growth.
Casdin Capital
A specialized investment firm focused on the life sciences sector, with deep expertise in financing diagnostic and molecular information companies that drive the next generation of healthcare innovation.
Janus Henderson Investors
A global asset management firm that leverages in-depth research and market expertise to deliver strong outcomes for institutional investors and financial professionals across diverse market conditions.
What's next for SomaLogic?
Following the recent influx of capital, SomaLogic is well-positioned to scale its commercial operations and expand the utility of its proteomics platform. The company's strategic roadmap likely involves deepening its footprint in clinical diagnostics and accelerating the adoption of its technology within the pharmaceutical R&D pipeline. As the industry shifts toward more personalized healthcare solutions, SomaLogic's ability to provide actionable, data-driven insights will be pivotal. Future growth will likely focus on enhancing the platform's throughput capabilities and broadening its application across diverse therapeutic areas, ensuring the company remains at the forefront of the multi-omics revolution.
See full SomaLogic company page
